Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Silverstein Eye Centers

Neither a doctor nor a teaching hospital

Research payments

$298,619

54 payments

Through program year 2025, Silverstein Eye Centers is reported as receiving $298,619 in research payments, across 54 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $19,816 3
2024 Research $10,992 3
2023 Research $19,000 7
2022 Research $28,895 12
2021 Research $14,868 3
2020 Research $151,563 11
2019 Research $53,487 15

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $165,903 7 payments
  2. AbbVie, Inc. $78,695 24 payments
  3. Kala Pharmaceuticals, Inc. $20,800 11 payments
  4. Alcon Research LLC $16,966 1 payment
  5. Allergan Inc. $8,332 3 payments
  6. EyePoint Pharmaceuticals US, Inc. $3,680 1 payment
  7. Sun Pharmaceutical Industries Inc. $3,656 6 payments
  8. Shire North American Group Inc $588 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $146,673 2 payments
  2. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $40,767 16 payments
  3. Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease $20,800 11 payments
  4. A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $17,532 2 payments
  5. Evaluation of the Clinical Efficacy and Tolerability of SYSTANE Complete in Adult Patients With Dry Eye Disease Following Topical Ocular Use for 4 Weeks: A Multicenter Trial $16,966 1 payment
  6. A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $10,254 1 payment
  7. Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia $7,120 2 payments
  8. Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension $6,084 1 payment
  9. A Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of Ecf843 VS Vehicle in Subjects With Dry Eye Disease $4,672 1 payment
  10. A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $4,000 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Other $3,656 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record